mogamulizumab-kpkc (Poteligeo)

Indications

• treatment of relapsed or refractory mycosis fungoides or Sezary syndrome after 1 prior systemic therapy

Dosage

• 4 mg/mL 5 mL (injection)

Adverse effects

common

• rash, infusion-related reactions, fatigue, diarrhea, musculoskeletal pain, upper respiratory tract infection.

serious

• dermatologic toxicity, infusion reactions, infections, autoimmune disorders
• complications of allogeneic stem cell transplantation after treatment with the drug

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• monoclonal Ab that binds to CC chemokine receptor-4 (CCR4)

More general terms

• antineoplastic monoclonal antibody